As the global medical AI industry enters a critical phase of large-scale implementation, YIDU TECH (02158), an AI-driven healthcare company, has delivered a half-year performance report highlighting business resilience and improved profitability. According to its interim results announcement for FY2026 released on November 27, the company benefited from favorable industry policies and effectively stimulated market demand, achieving significant growth in order volume. Total revenue reached RMB358 million, an 8.7% year-on-year increase, while losses narrowed sharply by 72%, nearing breakeven.

By business segment, the Big Data Platform and Solutions (AI for Medical) division demonstrated steady performance, generating RMB153 million in revenue, up 14.6% YoY. The segment expanded its client coverage, now serving 127 leading Chinese hospitals and 44 regulatory agencies and policymakers. The Life Science Solutions (AI for Life Science) segment recorded revenue of RMB138 million, maintaining strong customer loyalty with 17 out of the top 20 multinational pharmaceutical companies as clients. During the reporting period, the company supported multiple projects with significant clinical value.

Boosted by supportive industry policies, the Health Management Platform and Solutions (AI for Care) segment saw revenue surge 30.3% YoY to RMB66.67 million. Notably, YIDU TECH's "Shenzhen Huiminbao" insurance program, which it has operated for three consecutive years, reached a record-high participation of over 6.15 million people.

Analysts suggest that YIDU TECH's steady revenue growth, substantial reduction in losses, and improved cash flow in the first half of the fiscal year reflect the success of its strategic focus and operational efficiency. With ample cash reserves and an end-to-end ecosystem, the company is well-positioned to drive innovation and achieve sustainable profitability as the AI healthcare industry transitions from technological development to systematic empowerment.